共 26 条
[1]
Scheinberg MA(2014)Biosimilars in rheumatology: perspective and concerns Rheumatology (Oxford) 53 389-390
[2]
Azevedo VF(2017)A practical guide about biosimilar data for health care providers treating inflammatory diseases Biologics 11 13-21
[3]
Markenson J(2017)Biosimilars: the US regulatory framework Annu Rev Med 68 243-254
[4]
Alvarez DF(2017)The language of biosimilars: Clarification, definitions, and regulatory aspects Drugs 77 671-677
[5]
Jacobs I(2015)Biosimilars in India J Proteome 127 71-72
[6]
Kirchhoff C(2016)Japanese regulation of biosimilar products: past experience and current challenges Br J ClinPharmacol 82 30-40
[7]
Christl LA(2014)Clinical development and trial design of biosimilar products: a Japanese perspective J Biopharm J Biopharm Stat 24 1165-1172
[8]
Woodcock J(2013)Biosimilar development and regulation in Japan Generics and Biosimilars Initiative Journal (GaBI Journal) 2 207-208
[9]
Kozlowski S(2011)Regulatory guideline for biosimilar products in Korea Biologicals 39 336-338
[10]
Declerck P(2011)Registration of similar biological products—Singapore’s approach Biologicals 39 343-345